Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
VEA has quietly outpaced the S&P 500 over the past year, and the gap is widening in 2026, but a longer look at the scoreboard raises a question every U.S.-heavy investor needs to sit with before adding international exposure.
SPGM's total-world approach delivered 23.1% one-year gains versus IEFA's 19.9%, though the iShares fund offers higher dividend income and lower costs.
One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.
Both funds track 400+ financial stocks with nearly identical sector weights. VFH offers a larger asset base and slightly higher yield, while FNCL charges a lower expense ratio.
Dividend ETFs are quietly outrunning tech stocks in 2026, and a soft rotation is pulling serious capital away from the usual winners. Three overlooked funds stand to catch the biggest wave before most investors even notice the shift.
SPGM includes emerging markets and small-cap exposure that URTH lacks, while delivering stronger one-year returns despite similar volatility profiles.
Since July 2021, the S&P 500 has delivered a total return of 71%. But one standout stock has nearly doubled the market - over the past five years, Live Nation has surged 126% to $180.98 per share. Its momentum hasn’t stopped as it’s also gained 29.5% in the last six months thanks to its solid quarterly results, beating the S&P by 21.1%.
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Transcat has had an impressive run over the past six months as its shares have beaten the S&P 500 by 25.9%. The stock now trades at $86.15, marking a 34.3% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Some retirees are stacking five specific stocks into permanent positions and expecting the quarterly checks to outlast every market cycle. The yields look almost too good to be real, but the coverage ratios and raise streaks tell a different story.
Over the last six months, Elastic’s shares have sunk to $62.75, producing a disappointing 9.7% loss - a stark contrast to the S&P 500’s 8.4% gain. This might have investors contemplating their next move.
(Updates with index/price moves and company/geopolitical news from the first paragraph.) US equit
All three major indexes are climbing together for a change. Semiconductor stocks deserve most of the credit.
These exchange-traded funds (ETFs) have low fees and offer strong diversification, making them enticing options to just buy and hold.
The Russell 2000's lack of exposure to AI has made the once-risky index shockingly reliable in recent weeks. It’s up nearly 20% in 2026, which is the best it has done through July 21 of a year since 2013, according to Dow Jones Market Data. The Russell’s furious rally has come in the face of rising interest-rate expectations.
Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has gained 8.4%.
Markel Group has been treading water for the past six months, recording a small loss of 4.1% while holding steady at $1,975. The stock also fell short of the S&P 500’s 8.4% gain during that period.
GoodRx has had an impressive run over the past six months as its shares have beaten the S&P 500 by 13.1%. The stock now trades at $3.14, marking a 21.5% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
When the VIX spikes, most income investors reach for the same handful of dividend funds without knowing how differently each one behaves under real market stress. Four ETFs claim to solve the same problem, but only one of them is built for the job you actually need done.
Over the past six months, Asure Software’s shares (currently trading at $7.91) have posted a disappointing 17.1% loss, well below the S&P 500’s 8.4% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
IXUS offers broad, low-cost diversification across thousands of non-U.S. stocks with a higher dividend yield, while NZAC's climate-focused approach has delivered slightly better five-year returns.
Over the past six months, Tecnoglass’s stock price fell to $46.13. Shareholders have lost 12.1% of their capital, which is disappointing considering the S&P 500 has climbed by 8.4%. This may have investors wondering how to approach the situation.
Dycom trades at $410.10 per share and has stayed right on track with the overall market, gaining 9.2% over the last six months. At the same time, the S&P 500 has returned 8.4%.
Royal Caribbean has been treading water for the past six months, recording a small return of 2.8% while holding steady at $285.50. The stock also fell short of the S&P 500’s 8.4% gain during that period.
Giverny Capital Asset Management, LLC, an investment management company, recently published its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The model portfolio returned 13.70% this quarter, compared to the S&P 500’s 15.20% return. YTD, the portfolio gained 5.89%, while the index increased by 10.21%. The long-term link between stock […]
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
